URGENT UPDATE: A federal jury in California has just determined that Apple Inc. must pay $634 million to Masimo Corporation for infringing on their blood-oxygen sensor patent. This landmark ruling, delivered on Friday, marks a pivotal moment in the ongoing legal battle between the tech giant and the medical-monitoring firm.
The jury’s decision underscores the significance of protecting technological innovations. Masimo hailed the verdict as “a significant win in our ongoing efforts to protect our innovations and intellectual property,” reinforcing the importance of patent rights in the tech industry.
The conflict traces back to 2023 when Apple removed the blood-oxygen monitoring feature from its Apple Watch Series 9 and Ultra 2 to sidestep a potential sales ban. This preemptive move followed a ruling by the International Trade Commission (ITC) that found Apple’s sensors infringed on Masimo’s patents. By offering a modified version of their watches, Apple aimed to maintain its presence in the U.S. market without disruption.
However, in August 2024, Apple reintroduced the blood-oxygen feature after securing approval from U.S. Customs and Border Protection for imports of the devices. This decision reignited the legal dispute, prompting Masimo to challenge Apple’s actions in court, given the prior infringement ruling.
Market analysts are closely monitoring the stock performance of both companies. According to Benzinga Edge Stock Rankings, Apple boasts a growth score of 96.81% and a momentum rating of 77.08%. Year-to-date, Apple shares have risen by 11.71%, while Masimo’s stock has declined by 10.35%.
The outcome of this case could have significant implications for both companies and the tech industry as a whole. As Masimo fights to protect its intellectual property, the ruling may set a precedent for future patent disputes.
What happens next? Analysts will be watching closely for Apple’s response to the verdict and any potential appeals. The tech industry is abuzz with speculation on how this ruling may affect Apple’s product lineup and market strategy moving forward.
Stay tuned for updates as this story develops.